At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNTC Benitec Biopharma
Market Closed 11-13 16:00:00 EST
9.04
-0.05
-0.55%
盘后9.04
+0.000.00%
16:10 EST
High9.36Low8.69Vol144.69K
Open9.17D1 Closing9.09Amplitude7.37%
Mkt Cap315.34MTradable Cap174.35MTotal Shares34.88M
T/O1.31MT/O Rate0.75%Tradable Shares19.29M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Benitec Biopharma Inc Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  11-13 23:04
Benitec Biopharma Inc Reports Results for the Quarter Ended September 30 - Earnings Summary
Press Release: Updated
Dow Jones  ·  11-13 22:12
Press Release: Updated
Benitec Biopharma Q1 Net Loss Widens on Higher R&D Costs
Reuters  ·  11-13 21:14
Benitec Biopharma Q1 Net Loss Widens on Higher R&D Costs
Benitec Biopharma Q1 EPS $(0.26) Beats $(0.29) Estimate
Benzinga Earnings  ·  11-13 21:13
Benitec Biopharma Q1 EPS $(0.26) Beats $(0.29) Estimate
Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
THOMSON REUTERS  ·  11-13 21:00
Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Benitec Biopharma - Qtrly Net Loss Per Share $0.26
THOMSON REUTERS  ·  11-13 21:00
Benitec Biopharma - Qtrly Net Loss Per Share $0.26
Benitec Biopharma Inc Expected to Post a Loss of 29 Cents a Share - Earnings Preview
Reuters  ·  11-11
Benitec Biopharma Inc Expected to Post a Loss of 29 Cents a Share - Earnings Preview
US Research Roundup-Baker Hughes, Brinker International, GE Vernova
Reuters  ·  10-29
US Research Roundup-Baker Hughes, Brinker International, GE Vernova
Benitec Biopharma Inc : Raymond James Raises Target Price to $17 from $14
THOMSON REUTERS  ·  10-29
Benitec Biopharma Inc : Raymond James Raises Target Price to $17 from $14
Benitec Biopharma Reports 100% Response Rate in Interim BB-301 Phase 1b/2a Trial Results
Reuters  ·  10-28
Benitec Biopharma Reports 100% Response Rate in Interim BB-301 Phase 1b/2a Trial Results
Benitec Biopharma - Announces Positive Interim Phase 1B/2a Results for High and Low Dose Bb-301
THOMSON REUTERS  ·  10-28
Benitec Biopharma - Announces Positive Interim Phase 1B/2a Results for High and Low Dose Bb-301
Benitec Biopharma - no Serious Adverse Events Reported in Bb-301 Patients to Date
THOMSON REUTERS  ·  10-28
Benitec Biopharma - no Serious Adverse Events Reported in Bb-301 Patients to Date
Raymond James Initiates Coverage on Benitec Biopharma With Outperform Raring, $14 PT
MT Newswires Live  ·  10-23
Raymond James Initiates Coverage on Benitec Biopharma With Outperform Raring, $14 PT
Benitec Biopharma Inc : Raymond James Initiates Coverage with Outperform Rating; Target Price $14
THOMSON REUTERS  ·  10-23
Benitec Biopharma Inc : Raymond James Initiates Coverage with Outperform Rating; Target Price $14
US Research Roundup- Amgen, Lockheed Martin, Norfolk Southern
Reuters  ·  10-23
US Research Roundup- Amgen, Lockheed Martin, Norfolk Southern
FDA Clarity on BB-301 Phase 3 Supports Buy Rating on BNTC; $17 Price Target Reiterated
TIPRANKS  ·  10-06
FDA Clarity on BB-301 Phase 3 Supports Buy Rating on BNTC; $17 Price Target Reiterated
Benitec Biopharma says BB-301 pivotal still on track for mid-2027
TIPRANKS  ·  10-05
Benitec Biopharma says BB-301 pivotal still on track for mid-2027
Benitec Biopharma Targets Mid-2027 Start for BB-301 Pivotal Trial in OPMD Dysphagia
Reuters  ·  10-05
Benitec Biopharma Targets Mid-2027 Start for BB-301 Pivotal Trial in OPMD Dysphagia
Benitec Biopharma - Patient Enrollment for Bb-301 Pivotal Study Planned to Begin in Mid-2027
THOMSON REUTERS  ·  10-05
Benitec Biopharma - Patient Enrollment for Bb-301 Pivotal Study Planned to Begin in Mid-2027
Benitec Biopharma - FDA Requests Additional Data for Bb-301 Pivotal Study Including Opmd Natural History Study Data
THOMSON REUTERS  ·  10-05
Benitec Biopharma - FDA Requests Additional Data for Bb-301 Pivotal Study Including Opmd Natural History Study Data

Introduction

Company Name.
Benitec Biopharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Issue price:
--